Greenwich LifeSciences Provides Update on Patent Claims Potentially Doubling GP2 Market Potential
Rhea-AI Summary
Greenwich LifeSciences (Nasdaq: GLSI) updated investors on new patent claims tied to FLAMINGO-01 data for GLSI-100. The company says claims, based on statistically significant open‑label immune response and recurrence-rate data, could expand the GP2 market by 100% to 88,000 patients/year and enable combined approvals.
The invention is solely owned by the company; if granted after prosecution, the patent could provide protection through 2045. The company may sequence GP2-specific T cells to deepen immune-response analysis.
AI-generated analysis. Not financial advice.
Positive
- Market +100% to 88,000 patients per year
- Revenue potential up to $10 billion per year
- Patent could provide protection through 2045
- Enrollment now includes both HLA-A*02 and non-HLA-A*02 patients
Negative
- Patent claims are not yet granted; require successful prosecution
- Expanded approval for non-HLA patients is optional, not guaranteed
- Claims rely on statistically significant open‑label data rather than blinded readout
News Market Reaction – GLSI
On the day this news was published, GLSI gained 2.18%, reflecting a moderate positive market reaction. Argus tracked a peak move of +7.5% during that session. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $7M to the company's valuation, bringing the market cap to $345.81M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
GLSI fell 3.46% while momentum peers showed mixed moves: KYTX up 2.23% and AGEN down 3.45%. Broader biotech peers in the watchlist also show both gains and losses, pointing to stock-specific dynamics around this patent update.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 19 | Trial site expansion | Positive | -3.1% | Added City of Hope network sites, expanding FLAMINGO-01 U.S. coverage. |
| Mar 18 | Conference abstracts | Positive | -11.1% | AACR 2026 abstracts accepted with immune-response data and design update. |
| Mar 17 | Efficacy update | Positive | +6.8% | Open-label non-HLA-A*02 arm showed markedly reduced recurrence rate. |
| Mar 16 | Commercial supply | Positive | +8.4% | First commercial GP2 lot FDA-approved and supplied to all U.S. sites. |
| Mar 03 | Enrollment momentum | Positive | -0.5% | Screening rate rose above 800 patients per year across US/EU sites. |
Recent FLAMINGO-01 updates and trial progress headlines have often been followed by mixed to negative next-day moves, even when news skewed positive.
Over the last month, GLSI has issued multiple updates tied to its Phase III FLAMINGO-01 trial and commercialization readiness. On Mar 16 and Mar 17, FDA-cleared commercial GP2 supply and strong recurrence data led to positive price reactions. However, site expansion on Mar 19, AACR abstract news on Mar 18, and higher screening rates on Mar 3 all saw modest to sharp declines. Today’s patent-claims news fits into a string of clinically oriented, expansionary updates.
Market Pulse Summary
This announcement highlights new patent claims for GLSI-100, grounded in statistically significant immune-response and recurrence-rate data, that could expand eligibility to non-HLA-A*02 patients and potentially double the GP2 market to up to $10 billion per year. It also points to possible patent protection through 2045 and deeper T-cell sequencing work. Investors may track FLAMINGO-01 enrollment across HLA types and regulators’ views on these broadened claims in future updates.
Key Terms
immunotherapy medical
open label medical
recurrence rate medical
hla-a*02 medical
t cells medical
randomized arms medical
fast track regulatory
dna medical
AI-generated analysis. Not financial advice.
STAFFORD, Texas, April 07, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided an update on new patent claims based on FLAMINGO-01 statistically significant open label immune response and recurrence rate data.
- Statistically significant immune response and recurrence rate data is the basis for new claims recently filed that GLSI-100 clinically benefits non-HLA-A*02 patients, which the Company believes increases the market for GLSI-100 by an additional
100% to 88,000 new patients per year in the US and Europe. - The claims also show a favorable comparison to the blinded HLA-A*02 arms of FLAMINGO-01, without any unblinding.
- The invention is solely owned by the Company. If the patent claims are granted, following successful patent prosecution, the patent could provide patent protection through 2045.
The Company plans to expand its immune response analysis of GP2 specific T cells by sequencing the DNA of a patient's T cells at baseline and after treatment with GP2. The T cell sequences can be compared to the immune response changes over time.
CEO Snehal Patel commented, "We believe that these patent claims, based on statistically significant data, support the enrollment of patients independent of HLA type. In the US, we have already started to enroll both HLA-A*02 and non-HLA-A*02 patients in the same randomized arms in FLAMINGO-01, based on the FDA’s recent review of such protocol changes. The Company will have the option to pursue approval for both HLA-A*02 and non-HLA-A*02 patients using the increased statistical power of a combined analysis of the two patient groups together with the potential to double the market for GP2 to up to
About FLAMINGO-01 Open Label Phase III Data
More than 1,000 patients have been screened with a current screen rate of approximately 800 patients per year. The 250 patient non-HLA-A*02 arm is now fully enrolled, where all patients received GLSI-100, which is 5 times more treated patients and recurrence rate data than the approximately 50 patients treated in the Phase IIb trial. The Primary Immunization Series (PIS), which includes the first 6 GLSI-100 injections over the first 6 months and is required to reach peak protection, is followed by 5 booster injections given every 6 months to prolong the immune response, thereby providing longer-term protection.
- In the non-HLA-A*02 arm, a preliminary analysis of recurrence rates after the PIS is completed shows an approximately
80% reduction in recurrence rate. - This observation is trending similarly to the Phase IIb trial results and hazard ratio where HLA-A*02 patients were treated and where breast cancer recurrences were reduced up to
80% compared to a 20-50% reduction in recurrence rate by other approved products. - The immune response at baseline prior to any GLSI-100 treatment, the increasing immune response during the PIS, and the safety profile of non-HLA-A*02 patients is trending similarly to the HLA-A*02 arms of FLAMINGO-01 and to the Phase IIb study.
Analysis of the open label data from FLAMINGO-01 has been conducted in a manner that maintains the study blind. The open label recurrence rate, immune response, and safety data is based on the patients enrolled to date in FLAMINGO-01 and the data provided by the clinical sites so far, which is not completed or fully reviewed, and is thus preliminary. While comparing any preliminary FLAMINGO-01 data to the Phase IIb clinical trial data may be possible, these preliminary results are not a prediction of future results, and the results at the end of the study may differ.
About GLSI-100 Phase IIb Study
In the prospective, randomized, single-blinded, placebo-controlled, multi-center (16 sites led by MD Anderson Cancer Center) Phase IIb clinical trial of HLA-A*02 breast cancer patients, 46 HER2/neu 3+ over-expressor patients were treated with GLSI-100, and 50 placebo patients were treated with GM-CSF alone. After 5 years of follow-up, there was an
80% or greater reduction in metastatic breast cancer recurrence rate over 5 years of follow-up with a peak immune response at 6 months and well-tolerated safety profile.- The PIS elicited a potent immune response as measured by local skin tests and immunological assays.
About FLAMINGO-01 and GLSI-100
FLAMINGO-01 (NCT05232916) is a Phase III clinical trial designed to evaluate the safety and efficacy of Fast Track designated GLSI-100 (GP2 + GM-CSF) in HER2 positive breast cancer patients who had residual disease or high-risk pathologic complete response at surgery and who have completed both neoadjuvant and postoperative adjuvant trastuzumab based treatment. The trial is led by Baylor College of Medicine and currently includes US and European clinical sites from university-based hospitals and academic and cooperative networks with plans to open up to 150 sites globally. In the double-blinded arms of the Phase III trial, approximately 500 HLA-A*02 patients are planned to be randomized to GLSI-100 or placebo, and up to 250 patients of other HLA types are planned to be treated with GLSI-100 in a third arm. The trial has been designed to detect a hazard ratio of 0.3 in invasive breast cancer-free survival, where 28 events will be required. An interim analysis for superiority and futility will be conducted when at least half of those events, 14, have occurred. This sample size provides
For more information on FLAMINGO-01, please visit the Company's website here and clinicaltrials.gov here. Contact information and an interactive map of the majority of participating clinical sites can be viewed under the "Contacts and Locations" section. Please note that the interactive map is not viewable on mobile screens. Related questions and participation interest can be emailed to: flamingo-01@greenwichlifesciences.com
About Breast Cancer and HER2/neu Positivity
One in eight U.S. women will develop invasive breast cancer over her lifetime, with approximately 300,000 new breast cancer patients and 4 million breast cancer survivors. HER2 (human epidermal growth factor receptor 2) protein is a cell surface receptor protein that is expressed in a variety of common cancers, including in
About Greenwich LifeSciences, Inc.
Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2 protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in
Forward-Looking Statement Disclaimer
Statements in this press release contain "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will," "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Greenwich LifeSciences Inc.'s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including statements regarding the intended use of net proceeds from the public offering; consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section entitled "Risk Factors" in Greenwich LifeSciences' Annual Report on the most recent Form 10-K for the year ended December 31, 2024, and other periodic reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Greenwich LifeSciences, Inc. undertakes no duty to update such information except as required under applicable law.
Company Contact
Snehal Patel
Investor Relations
Office: (832) 819-3232
Email: info@greenwichlifesciences.com
Investor & Public Relations Contact for Greenwich LifeSciences
Dave Gentry
RedChip Companies Inc.
Office: 1-800-RED CHIP (733 2447)
Email: dave@redchip.com
